IC50: 3.04 nM (AKR1C3)[1]
S19-1035 is a highly potent and specific aldo-keto reductase 1C3 (AKR1C3) inhibitor. S19-1035 inhibits AKR1C3 with an IC50 value of 3.04 nM. S19-1035 can be used for the research of tumor[1].
S19-1035 对 AKR1C3 具有抑制活性，其 IC50 值为 3.04 nM[1]。
S19-1035 (0-100 μM; 72 h or 96 h) 的细胞毒性较小，单独使用时抗肿瘤作用有限[1]。
S19-1035 (10 μM; 8 days) 显著逆转耐药乳腺癌细胞株的多柔比星（DOX）耐药性[1]。
Cell Cytotoxicity Assay[1]
| Cell Line: | MDA-MB-231, MCF-7 and MCF-7/DOX cells |
| Concentration: | 0-100 μM |
| Incubation Time: | 72 h or 96 h |
| Result: | Had weak antiproliferative effects in all three breast cancer cell lines. |
[1]. Yang Liu, et al. Development of highly potent and specific AKR1C3 inhibitors to restore the chemosensitivity of drug-resistant breast cancer. Eur J Med Chem. 2022 Dec 13;247:115013.